@article{e67ccfe9585948e9b36d5005075f3061,
title = "Susceptibility of renal fibrosis in diabetes: Role of hypoxia inducible factor-1",
abstract = "Diabetes may prevent kidney repair and sensitize the kidney to fibrosis or scar formation. To test this possibility, we examined renal fibrosis induced by unilateral ureteral obstruction (UUO) in diabetic mouse models. Indeed, UUO induced significantly more renal fibrosis in both Akita and STZ-induced diabetic mice than in nondiabetic mice. The diabetic mice also had more apoptosis and interstitial macrophage infiltration during UUO. In vitro, hypoxia induced higher expression of the fibrosis marker protein fibronectin in high glucose-conditioned renal tubular cells than in normal glucose cells. Mechanistically, hypoxia induced significantly more hypoxia-inducible factor-1 α (HIF-1 α) in high glucose cells than in normal glucose cells. Inhibition of HIF-1 attenuated the expression of fibronectin induced by hypoxia in high-glucose cells. Consistently, UUO induced significantly higher HIF-1α expression along with fibrosis in diabetic mice kidneys than in nondiabetic kidneys. The increased expression of fibrosis induced by UUO in diabetic mice was diminished in proximal tubule-HIF-1α-knockout mice. Together, these results indicate that diabetes sensitizes kidney tissues and cells to fibrogenesis probably by enhancing HIF-1 activation.",
keywords = "diabetic kidney disease, fibrosis, HIF-1, high glucose",
author = "Shuqin Mei and Lin Li and Xiangjun Zhou and Cheng Xue and Livingston, {Man J.} and Qingqing Wei and Bing Dai and Zhiguo Mao and Changlin Mei and Zheng Dong",
note = "Funding Information: We thank Dr. Volker Haase at Vanderbilt University School of Medicine (Nashville, TE), Dr. Ulrich Hopfer at Case Western Reverse University (Cleveland, OH), and Drs. Lieberthal and Schwartz at Boston University (Boston, MA) for generously providing PEPCK-CRE transgenic mice, RPTC line, and mouse PT cell (BUMPT-306) line, respectively. This study was supported by grant from National Natural Science Foundation of China (81873595, 81800681) and Shanghai Municipal Key Clinical Specialty (shslczdzk02503). Zheng Dong is a recipient of the Senior Research Career Scientist award from the Department of Veterans Affairs of USA, supported by the Department of Veterans Affairs of USA (1TK6BX005236, I01 BX000319) and the National Institutes of Health of USA (5R01DK058831, 5R01DK087843). Funding Information: We thank Dr. Volker Haase at Vanderbilt University School of Medicine (Nashville, TE), Dr. Ulrich Hopfer at Case Western Reverse University (Cleveland, OH), and Drs. Lieberthal and Schwartz at Boston University (Boston, MA) for generously providing PEPCK‐CRE transgenic mice, RPTC line, and mouse PT cell (BUMPT‐306) line, respectively. This study was supported by grant from National Natural Science Foundation of China (81873595, 81800681) and Shanghai Municipal Key Clinical Specialty (shslczdzk02503). Zheng Dong is a recipient of the Senior Research Career Scientist award from the Department of Veterans Affairs of USA, supported by the Department of Veterans Affairs of USA (1TK6BX005236, I01 BX000319) and the National Institutes of Health of USA (5R01DK058831, 5R01DK087843). Publisher Copyright: {\textcopyright} 2022 Federation of American Societies for Experimental Biology.",
year = "2022",
month = aug,
doi = "10.1096/fj.202200845R",
language = "English (US)",
volume = "36",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "8",
}